Bristol Myers Squibb Acquires Orum's ORM-6151 Program For Upfront Payment Of $100M; Orum Eligible To Receive Milestones Of $180M
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb has acquired Orum's ORM-6151 program for an upfront payment of $100M. Orum is also eligible to receive milestones of $180M.
November 06, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's acquisition of Orum's ORM-6151 program could potentially enhance its product portfolio and future revenue streams.
The acquisition of Orum's ORM-6151 program by Bristol Myers Squibb represents a strategic move to enhance its product portfolio. The upfront payment of $100M and potential milestones of $180M indicate a significant investment by BMY, which could lead to increased revenues in the future if the program proves successful.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100